CTLA4 and neoplasm: Previous studies using oncolytic viruses to treat glioma [37, 38] led us to hypothesize that inhibitory receptors may be blunting the anti-tumor immune response, so we also added anti-CTLA-4 and anti-PD1 combination immune checkpoint blockade (ICB).